Stay updated on Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi
Sign up to get notified when there's something new on the Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi page.

Latest updates to the Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe page now shows a new revision tag, v3.6.6, replacing the previous v3.6.5. This indicates a minor platform or CMS update and does not alter the study information.SummaryDifference0.0%

- Check14 days agoChange DetectedA new line under Other Study ID Numbers adds a funding note for 2018.SummaryDifference0.0%

- Check22 days agoChange DetectedA plain-language summary of the SAVANNAH study has been added to the Study Details page, outlining the rationale and design of combining osimertinib with savolitinib in EGFRm+/MET+ NSCLC after progression on osimertinib. The previous plain-language summary citation line has been removed/updated to reflect the new entry.SummaryDifference0.0%

- Check29 days agoChange DetectedThe page's revision tag was updated to v3.6.5, replacing the previous v3.6.4 tag to reflect a newer version.SummaryDifference0.0%

- Check51 days agoChange DetectedA new plain-language publication citation for the SAVANNAH study was added, and the page revision is updated to v3.6.4, replacing v3.6.3.SummaryDifference0.1%

- Check72 days agoChange DetectedThe page now shows Revision: v3.6.3 and no longer displays Revision: v3.6.0, indicating a small metadata update to the study record page.SummaryDifference0.0%

Stay in the know with updates to Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi
Enter your email address, and we'll notify you when there's something new on the Clinical Trial: Osi+Sav in EGFRm+/MET+ NSCLC Post-Osi page.